Astellas Pharma Gets Positive CHMP Opinion For XTANDI In Early Prostate Cancer Treatment Setting

RTTNews | 280 days ago
Astellas Pharma Gets Positive CHMP Opinion For XTANDI In Early Prostate Cancer Treatment Setting

(RTTNews) - Astellas Pharma Inc. announced Friday the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of XTANDI (enzalutamide) as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.

The positive CHMP opinion is based on the results from the Phase 3 EMBARK trial.

The positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines in all 27 European Union (EU) member states as well as Iceland, Liechtenstein and Norway.

Astellas is also discussing the EMBARK data with other regulatory authorities to support additional license applications for XTANDI in this indication in 2024 and beyond.

read more
Swiss Market Ends On Firm Note

Swiss Market Ends On Firm Note

The Switzerland market closed on a firm note on Friday, in line with markets across Europe, as investors picked up stocks from across several sectors. The benchmark SMI closed up 101.06 points or 0.88% at 11,589.34, slightly off the day's high of 11,597.29.
RTTNews | 8h 38min ago
European Markets Close Higher

European Markets Close Higher

European stocks closed higher on Friday, as investors made some purchases at several counters as markets resumed trading after Christmas holidays. Activity was a bit subdued in most of the markets in the region amid a lack of triggers, and ahead of the New Year holidays coming up next week.
RTTNews | 8h 54min ago